Policy

Cleo Diagnostics (ASX:COV) has secured $5 million in capital to support its expansion into the United States and speed the development of a new mass screening test for ovarian cancer, in a raise that attracted strong backing from institutional and high-net-worth investors.

Actinogen Medical (ASX:ACW) has hit a significant milestone in its push to bring a new oral Alzheimer’s therapy to market, completing enrolment in its pivotal XanaMIA trial and confirming November 2026 for topline results.

OncoSil Medical (ASX:OSL) has marked a significant milestone in its manufacturing strategy, announcing the successful completion of the first 'hot' production test run at its new Sydney facility.

Island Pharmaceuticals (ASX:ILA) has taken a step forward in the development of its antiviral candidate galidesivir, securing a strategic partnership with the Texas Biomedical Research Institute, one of the world’s most advanced infectious disease centres and a critical player in high-containment pathogen research.

Australian medtech company Ferronova has raised a further $6 million to support the commercialisation of its image-guided cancer surgery technology.

A new antimalarial drug candidate developed through a long-running collaboration between Melbourne’s WEHI and MSD is showing promise in the fight against malaria, particularly as resistance to existing treatments continues to spread.

Radiopharm Theranostics (ASX:RAD) has announced encouraging interim results from its U.S.-based Phase 2b clinical imaging trial of RAD 101, reporting that 92 per cent of evaluable patients achieved concordance between RAD 101 PET imaging and MRI, the study’s primary endpoint.

MTPConnect has launched applications for its 2026 Pathway to Market – Medtech Capability Uplift Program, a Victorian initiative designed to help local medtech manufacturers secure procurement opportunities with hospitals and health services.

Amplia Therapeutics (ASX:ATX) has delivered an update on its clinical progress, announcing an additional confirmed partial tumour response in its ACCENT trial and presenting new data to investors that reinforce the potential of its FAK inhibitor narmafotinib in metastatic pancreatic cancer.

Mesoblast (ASX:MSB) has welcomed new research showing that its allogeneic cell therapy remestemcel-L delivers superior clinical outcomes compared with ruxolitinib for patients with steroid-refractory acute graft versus host disease.

Algorae Pharmaceuticals (ASX:1AI) has taken a significant step forward in AI-enabled drug discovery, announcing the completion of a sweeping set of in silico synergy predictions generated by its upgraded platform, AlgoraeOS v2.

Neuren Pharmaceuticals (ASX:NEU) has secured another significant regulatory milestone in its Rett syndrome program, announcing that partner Acadia Pharmaceuticals has received U.S. FDA approval for DAYBUE STIX, a new dye- and preservative-free powder formulation of trofinetide for oral solution.